This clinical trial is focused on studying the effects of a combination treatment for patients with rheumatoid arthritis, a chronic inflammatory disorder that primarily affects the joints. The study will evaluate the effectiveness of combining two types of medications: baricitinib, which is taken as a 4 mg tablet daily, and anti-TNF therapies, which include adalimumab (40 mg injection every two weeks) or etanercept (50 mg injection every week). These medications are being compared to the use of baricitinib alone. Anti-TNF therapies are a class of drugs that help reduce inflammation by blocking a protein called tumor necrosis factor (TNF) that is involved in the inflammatory process.

The purpose of the study is to assess how well the combination of these treatments works over a period of 24 weeks in patients whose rheumatoid arthritis has not responded adequately to previous treatments. Participants will be randomly assigned to receive either the combination of baricitinib and an anti-TNF therapy or baricitinib alone. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the actual treatments. The study will monitor the participants’ response to the treatment, including any changes in their symptoms and overall health.

Throughout the study, participants will have regular check-ups to track their progress and any side effects they may experience. The study aims to provide valuable information on whether the combination of baricitinib and anti-TNF therapies offers better outcomes for patients with rheumatoid arthritis compared to using baricitinib alone. This research could potentially lead to improved treatment options for those living with this condition.